Silence Therapeutics PLC (SLN) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $5.42
• Market Cap: $326.86M
• EPS: $-1.35
• 52-Week High: $7.78
• 52-Week Low: $1.97

Market Sentiment

Silence Therapeutics PLC currently has a Bullish sentiment score of 0.18.

About Silence Therapeutics PLC

Silence Therapeutics PLC is a London-based biotechnology company specializing in the development of innovative ribonucleic acid (RNA) therapies aimed at addressing unmet medical needs in hematology, cardiovascular diseases, and various rare and metabolic disorders. By leveraging its proprietary RNAi technology platform, Silence is positioned to advance transformative therapeutics that target specific disease mechanisms, offering potentially groundbreaking treatments for patients. With a robus...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Silence Therapeutics PLC and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does SLN pay dividends?

Silence Therapeutics PLC (SLN) does not currently pay a regular dividend.

What is SLN's market cap?

Silence Therapeutics PLC (SLN) has a market capitalization of $326.86M with a current stock price of $5.42.